Cardiovascular risks of androgen deprivation therapy for prostate cancer

被引：1
|
作者：
Miller, K. [1 ]
机构：
[1] Klin & Hsch Ambulanz Urol, Charitepl 1, D-10117 Berlin, Germany
来源：
UROLOGE | 2016年 / 55卷 / 05期
关键词：
Prostate cancer; Androgen deprivation therapy; Cardio vascular events; GnRH antagonists; LHRH agonists; MEN; DISEASE; ASSOCIATION; SUPPRESSION; MORBIDITY; MORTALITY;
D O I：
10.1007/s00120-015-0021-1
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Androgen deprivation therapy (ADT) is the standard treatment for metastatic prostate cancer. It has increasingly been used in other stages of the disease as well. Besides well-known side effects caused by the lack of testosterone (impotency, osteoporosis, fatigue, loss of muscle mass), an increase of cardiovascular (CV) morbidity and mortality has recently been discussed in association with ADT. Cardiovascular side effects cannot be sufficiently explained by low testosterone levels. This review gives an overview of the recent literature, interprets the results, and offers clinical consequences.
引用
收藏
页码：627 / 631
页数：5
相关论文
共 50 条
  • [1] Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
    Corona, Giovanni
    Filippi, Sandra
    Bianchi, Nicola
    Dicuio, Mauro
    Rastrelli, Giulia
    Concetti, Sergio
    Sforza, Alessandra
    Maggi, Mario
    WORLD JOURNAL OF MENS HEALTH, 2021, 39 (03) : 429 - 443
  • [2] Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer
    Gheorghe, Gabriela Silvia
    Hodorogea, Andreea Simona
    Ciobanu, Ana
    Nanea, Ioan Tiberiu
    Gheorghe, Andrei Cristian Dan
    CURRENT ONCOLOGY, 2021, 28 (05) : 3331 - 3346
  • [3] Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients
    Muniyan, Sakthivel
    Xi, Lei
    Datta, Kaustubh
    Das, Anindita
    Teply, Benjamin A.
    Batra, Surinder K.
    Kukreja, Rakesh C.
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2020, 1874 (01):
  • [4] Androgen deprivation therapy and cardiovascular complications
    Poljak, Z.
    Hulin, I
    Maruscakova, L.
    Carter, A.
    Mladosievicova, B.
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2016, 117 (10): : 557 - 561
  • [5] Cardiovascular risk during androgen deprivation therapy for prostate cancer
    Jones, Thomas Hugh
    BRITISH MEDICAL JOURNAL, 2011, 342
  • [6] Monitoring cardiovascular health in men with prostate cancer treated with androgen deprivation therapy
    Allan, Carolyn A.
    Collins, Veronica R.
    Frydenberg, Mark
    McLachlan, Robert I.
    Matthiesson, Kati L.
    INTERNATIONAL JOURNAL OF UROLOGICAL NURSING, 2012, 6 (01) : 35 - 41
  • [7] Cardiovascular Complications of Androgen Deprivation Therapy for Prostate Cancer
    Gupta D.
    Salmane C.
    Slovin S.
    Steingart R.M.
    Current Treatment Options in Cardiovascular Medicine, 2017, 19 (8)
  • [8] Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer
    Agarwal, Megha
    Canan, Timothy
    Glover, Greg
    Thareja, Nidhi
    Akhondi, Andre
    Rosenberg, Joshua
    CURRENT ONCOLOGY REPORTS, 2019, 21 (10)
  • [9] Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies
    Zapatero, A.
    Gonzalez San Segundo, C.
    Boladeras, A.
    Gomez Caamano, A.
    Lopez Torrecilla, J.
    Maldonado, X.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (03) : 223 - 229
  • [10] Androgen deprivation therapy and cardiovascular disease
    Melloni, Chiara
    Roe, Matthew T.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (02) : 45 - 52
12345